多药耐药P糖蛋白检测与急性白血病预后相关性研究  

Detection of multidrug resistance associated P glycoprotein and its correlation with prognosis in patients with acute leukaemia

作　　者：周绮楼 方定 汪月增[1] 冯凯[1] 阎影[1] 

机构地区：[1]解放军总医院血液科

出　　处：《军医进修学院学报》1997年第4期250-252,共3页Academic Journal of Pla Postgraduate Medical School

摘　　要：目的：探讨多药耐药（ＭＤＲ）Ｐ糖蛋白（Ｐ１７０）表达与急性白血病预后关系。方法：采用抗Ｐ１７０单克隆抗体ＪＳＢ－１及碱性磷酸酶抗碱性磷酸酶免疫细胞化学技术检测８６例（１０４例次）急性白血病骨髓细胞Ｐ１７０表达。结果：Ｐ１７０阳性率难治组为７６．９％（１０／１３），复发组４０．９％（９／２２），初治组２７％（１０／３７），完全缓解组１８．８％（６／３２）。初治组Ｐ１７０阴性病例首次诱导完全缓解（ＣＲ１）率８１．５％，Ｐ１７０阳性ＣＲ１率４０％（Ｐ＜０．０５）。复发组Ｐ１７０阴性患者再诱导化疗完全缓解（ＣＲ２）率３０．８％（４／１３），Ｐ１７０阳性患者ＣＲ２率１１．１％（１／９）。结论：Ｐ１７０表达与急性白血病缓解、复发及耐药有关。Ｐ１７０检测有助于判断急性白血病疗效及预后。Objective:To evaluate the clinical value of the expression of multidrug resistance (MDR) P glycoprotein (P 170 in patients with acute leukaemia. Methods:104 specimens were analyzed from 86 patients with acute leukaemia by using monoclonal JSB 1 with immunocytochemical staining technique of alkline phosphatase anti alkaline phosphatase( APAAP). Results:That P 170 positive cases were 76.9% (10/13) in refractory group, 40.9% (9/22) in relapse group, 27% (10/37) in fresh case group and 18.8% (6/32) in complete remission group, respectvely. The lst induction remission rate (CR) was 81.5%(22/27) in P 170 negative cases and 40% (4/10) in P 170 positive cases in fresh case group ( P <0.05). The second remission rate (CR 2) was 30.8%(4/13) and 11.9%(1/9) in P 170 negative and P 170 positive in relapsed patients respectively. the relapse rate was also different in patients with CR of 25% (11/44) in P 170 negative and 70% (7/10) in P 170 positive cases ( P <0.05). Conclusion:It is suggested that P 170 expression is significantly associated with the clinical resistance to chemotherapy. The detection of P 170 may be a useful method of predicting theraputic response and designing treatment protocols drug resistant in leukaemia patients.

关 键 词：白血病 急性 P糖蛋白 药物耐药性 预后 

分 类 号：R733.710.7[医药卫生—肿瘤]